mechanism of action glp-1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Consensus Recommendations on GLP-1 RA

The number of therapeutic options is limited and are often associated with adverse side effects

Learn how GLP-1 agonists impact weight loss, metabolism, & cognitive health

GLP-1 receptor agonists used for the treatment of diabetes, have shown some neuroprotective effects in cellular and animal models of Alzheimers disease (AD) and Parkinsons disease (PD)

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

Mounjaro kan ekeri seviyelerini kontrol etmede ve kilo kaybn salamada ok

Tirzepatide is once-weekly injectable, dual glucagon-like peptide 1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist